



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

February 2016





HIV/AIDS Drug Treatment Program

Monthly Report

© 2016 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

February 2016

N = 6998



Health Authority	Male	Female	All
FRASER	1323	382	1705
INTERIOR	362	99	461
NORTHERN	134	75	209
VANCOUVER COASTAL	3338	450	3788
VANCOUVER ISLAND	650	149	799
	5807	1155	6962
		Unknown/not stated:	36
		Total:	6998

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (February 2011 - February 2016)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (February 2011 - February 2016)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (February 2011 - February 2016)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (February 2011 - February 2016)






1.6 Percent Distribution of Active Participants by CD4 Count (February 2011 - February 2016)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(February 2011 - February 2016)






1.8 Active and Inactive Participants (February 2011 - February 2016)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (February 2011 - February 2016)






**1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT
(February 2011 - February 2016)**






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(February 2011 - February 2016)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (February 2011 - February 2016)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(February 2011 - February 2016)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (February 2011 - February 2016)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(February 2011 - February 2016)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (February 2011 - February 2016)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(February 2011 - February 2016)






1.18 Baseline CD4 for Antiretroviral First Starts (February 2011 - February 2016)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(February 2011 - February 2016)**






1.20 Cumulative Resistance Testing Results by Resistance Category (February 2011 - February 2016)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (February 2011 - February 2016)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2016
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	24	5	0	5	5	810	5	<40	3
1988	24	7	0	7	7	540	7	<40	3
1989	23	57	2	59	51	510	57	<40	3
1990	22	64	1	65	61	510	65	<40	3
1991	22	37	3	40	36	600	40	<40	3
1992	22	69	7	76	60	595	76	<40	3
1993	20	147	15	162	147	550	158	<40	3
1994	20	94	13	107	88	580	105	<40	3
1995	19	124	25	149	120	540	143	<40	3
1996	17	373	61	434	376	590	415	<40	3
1997	15	306	40	346	308	610	332	<40	3
1998	15	214	46	260	210	560	243	<40	3
1999	14	187	40	227	189	550	216	<40	3
2000	15	138	38	176	151	540	171	<40	3
2001	14	133	30	163	135	610	157	<40	3
2002	13	141	32	173	139	590	166	<40	3
2003	12	172	35	207	177	600	198	<40	3
2004	11	183	46	229	194	550	215	<40	3
2005	10	212	49	261	223	580	252	<40	3
2006	9	215	45	260	206	560	244	<40	3
2007	8	281	56	337	285	570	320	<40	3
2008	7	318	70	388	322	640	361	<40	3
2009	7	349	77	426	362	650	408	<40	3
2010	6	318	73	391	323	640	368	<40	3
2011	5	366	83	449	382	645	431	<40	3
2012	4	300	68	368	318	700	356	<40	3
2013	3	302	71	373	307	650	358	<40	3
2014	2	317	58	375	310	676	359	<40	3
2015	1	357	59	416	366	570	406	<40	3
2016	0	34	16	50	46	435	45	5704	3
Total:		5820	1159	6979					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2015	6742	760	2430	<40	2114	580
FEB-2015	6792	753	1978	<40	1731	570
MAR-2015	6837	747	2173	<40	1897	570
APR-2015	6849	739	2149	<40	1908	580
MAY-2015	6888	739	2032	<40	1788	560
JUN-2015	6902	740	2254	<40	1962	580
JUL-2015	6927	739	2038	<40	1798	580
AUG-2015	6924	752	2075	<40	1774	580
SEP-2015	6924	749	2265	<40	1970	580
OCT-2015	6960	739	2102	<40	1801	590
NOV-2015	7017	721	2065	<40	1793	580
DEC-2015	6996	724	2016	<40	1751	600
JAN-2016	6986	735	2266	<40	1899	590
FEB-2016	6998	736	2065	<40	1716	590

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2015	1511	2045	105	1364	86	315
FEB-2015	1493	2120	101	78	86	380
MAR-2015	1467	2292	101	56	92	405
APR-2015	1473	2263	83	2239	68	465
MAY-2015	1456	2372	73	148	60	430
JUN-2015	1474	2295	96	106	89	430
JUL-2015	1468	2344	71	938	55	379
AUG-2015	1479	2304	82	2341	73	440
SEP-2015	1504	2232	91	128	79	349
OCT-2015	1484	2360	79	<40	64	405
NOV-2015	1455	2504	84	223	70	450
DEC-2015	1494	2324	78	384	61	330
JAN-2016	1504	2339	113	<40	85	460
FEB-2016	1503	2366	81	353	64	340

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2015	6709	1511	13	24	149	187	-34	11955
FEB-2015	6761	1493	7	36	188	162	52	12007
MAR-2015	6812	1467	7	29	174	143	51	12047
APR-2015	6811	1473	15	28	168	172	-1	12083
MAY-2015	6851	1456	9	33	171	149	40	12124
JUN-2015	6873	1474	5	36	153	160	22	12171
JUL-2015	6908	1468	5	25	166	149	35	12209
AUG-2015	6905	1479	7	19	145	157	-3	12239
SEP-2015	6901	1504	9	32	157	181	-4	12280
OCT-2015	6931	1484	14	25	172	147	30	12317
NOV-2015	6988	1455	9	29	186	147	57	12358
DEC-2015	6967	1494	11	22	150	181	-21	12391
JAN-2016	6962	1504	9	18	153	165	-5	12414
FEB-2016	6979	1503	5	18	173	165	17	12442

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2015	48	6180	440	74	6742	0.71%	91.66%	6.53%	1.10%	100.00%
FEB-2015	49	6219	451	73	6792	0.72%	91.56%	6.64%	1.07%	100.00%
MAR-2015	47	6287	436	67	6837	0.69%	91.96%	6.38%	0.98%	100.00%
APR-2015	46	6301	435	67	6849	0.67%	92.00%	6.35%	0.98%	100.00%
MAY-2015	47	6342	431	68	6888	0.68%	92.07%	6.26%	0.99%	100.00%
JUN-2015	49	6335	446	72	6902	0.71%	91.78%	6.46%	1.04%	100.00%
JUL-2015	46	6361	453	67	6927	0.66%	91.83%	6.54%	0.97%	100.00%
AUG-2015	48	6362	444	70	6924	0.69%	91.88%	6.41%	1.01%	100.00%
SEP-2015	48	6373	439	64	6924	0.69%	92.04%	6.34%	0.92%	100.00%
OCT-2015	51	6403	442	64	6960	0.73%	92.00%	6.35%	0.92%	100.00%
NOV-2015	54	6451	445	67	7017	0.77%	91.93%	6.34%	0.95%	100.00%
DEC-2015	52	6433	449	62	6996	0.74%	91.95%	6.42%	0.89%	100.00%
JAN-2016	53	6422	450	61	6986	0.76%	91.93%	6.44%	0.87%	100.00%
FEB-2016	52	6447	440	59	6998	0.74%	92.13%	6.29%	0.84%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	10 29%	2584 40%	10 29%	2221 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3847 59%	25 71%	4211 64%
FEB-2015	8 15%	2593 39%	8 15%	2228 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 85%	3883 59%	44 85%	4246 64%
MAR-2015	10 25%	2610 39%	10 25%	2253 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 75%	3916 59%	30 75%	4272 64%
APR-2015	10 29%	2626 40%	10 29%	2267 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	24 69%	3916 59%	24 69%	4272 64%
MAY-2015	8 20%	2640 40%	7 18%	2282 34%	0 0%	118 2%	0 0%	14 0%	0 0%	9 0%	32 80%	3929 59%	33 83%	4283 64%
JUN-2015	10 21%	2635 39%	10 21%	2289 34%	0 0%	115 2%	0 0%	15 0%	0 0%	9 0%	37 79%	3946 59%	37 79%	4297 64%
JUL-2015	4 11%	2659 40%	4 11%	2313 34%	0 0%	111 2%	0 0%	14 0%	0 0%	9 0%	34 89%	3947 59%	34 89%	4297 64%
AUG-2015	12 40%	2675 40%	11 37%	2334 35%	1 3%	111 2%	0 0%	12 0%	0 0%	9 0%	18 60%	3943 59%	18 60%	4283 64%
SEP-2015	17 41%	2715 40%	15 37%	2373 35%	0 0%	107 2%	1 2%	13 0%	0 0%	6 0%	24 59%	3912 58%	24 59%	4252 63%
OCT-2015	11 30%	2747 41%	10 27%	2404 36%	0 0%	102 2%	0 0%	13 0%	0 0%	8 0%	26 70%	3904 58%	27 73%	4242 63%
NOV-2015	17 41%	2790 41%	15 37%	2445 36%	1 2%	102 2%	0 0%	13 0%	0 0%	8 0%	24 59%	3916 58%	25 61%	4248 63%
DEC-2015	5 15%	2797 41%	5 15%	2458 36%	0 0%	95 1%	0 0%	12 0%	0 0%	8 0%	28 85%	3890 57%	28 85%	4215 62%
JAN-2016	4 17%	2825 42%	4 17%	2492 37%	0 0%	93 1%	0 0%	11 0%	0 0%	8 0%	19 83%	3862 57%	19 83%	4180 62%
FEB-2016	10 36%	2855 42%	9 32%	2523 37%	1 4%	94 1%	0 0%	11 0%	0 0%	8 0%	18 64%	3837 57%	18 64%	4144 61%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	0 0%	12 0%	6 50%	2030 60%	6 50%	931 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2030 60%	18 69%	960 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2044 60%	8 47%	971 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 0%
APR-2015	0 0%	12 0%	7 33%	2025 60%	14 67%	990 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%
MAY-2015	0 0%	12 0%	10 63%	2001 59%	6 38%	1020 30%	0 0%	360 11%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
JUN-2015	0 0%	11 0%	8 44%	1967 58%	10 56%	1037 31%	0 0%	359 11%	0 0%	5 0%	0 0%	1 0%	0 0%	18 1%
JUL-2015	0 0%	10 0%	1 7%	1959 58%	11 79%	1050 31%	1 7%	352 10%	0 0%	5 0%	0 0%	1 0%	1 7%	19 1%
AUG-2015	0 0%	11 0%	1 9%	1947 58%	7 64%	1054 31%	3 27%	346 10%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
SEP-2015	0 0%	11 0%	4 25%	1913 58%	11 69%	1061 32%	1 6%	338 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
OCT-2015	0 0%	10 0%	5 31%	1901 57%	10 63%	1088 33%	1 6%	331 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
NOV-2015	0 0%	10 0%	5 31%	1879 56%	9 56%	1108 33%	2 13%	329 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
DEC-2015	0 0%	11 0%	3 25%	1840 56%	8 67%	1119 34%	1 8%	328 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
JAN-2016	0 0%	11 0%	5 42%	1827 55%	6 50%	1132 34%	1 8%	327 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
FEB-2016	0 0%	10 0%	6 46%	1796 55%	6 46%	1162 35%	1 8%	318 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%
MAY-2015	0	0%	1	0%
JUN-2015	0	0%	1	0%
JUL-2015	0	0%	1	0%
AUG-2015	0	0%	1	0%
SEP-2015	0	0%	1	0%
OCT-2015	0	0%	1	0%
NOV-2015	0	0%	1	0%
DEC-2015	0	0%	1	0%
JAN-2016	0	0%	1	0%
FEB-2016	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose



2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	900 34%	2 25%	253 10%
FEB-2015	4 50%	1169 45%	0 0%	306 12%	0 0%	892 34%	4 50%	250 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	889 34%	1 13%	255 10%
APR-2015	4 67%	1148 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%
MAY-2015	7 58%	1139 44%	1 8%	309 12%	0 0%	887 34%	4 33%	260 10%
JUN-2015	2 29%	1133 44%	0 0%	317 12%	0 0%	877 34%	5 71%	262 10%
JUL-2015	8 89%	1122 44%	0 0%	311 12%	0 0%	880 34%	1 11%	260 10%
AUG-2015	4 80%	1104 43%	0 0%	307 12%	0 0%	879 35%	1 20%	253 10%
SEP-2015	8 89%	1097 43%	1 11%	305 12%	0 0%	873 35%	0 0%	256 10%
OCT-2015	2 50%	1084 43%	0 0%	312 12%	1 25%	867 35%	1 25%	251 10%
NOV-2015	4 67%	1076 43%	0 0%	312 12%	0 0%	865 35%	2 33%	254 10%
DEC-2015	3 100%	1059 43%	0 0%	312 13%	0 0%	863 35%	0 0%	254 10%
JAN-2016	3 100%	1038 42%	0 0%	302 12%	0 0%	855 35%	0 0%	256 10%
FEB-2016	3 60%	1009 42%	0 0%	306 13%	1 20%	857 35%	1 20%	260 11%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	13 72%	541 30%	4 22%	349 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 58%	577 31%	8 33%	355 19%	0 0%	74 4%	2 8%	880 48%	0 0%	1 0%
MAR-2015	9 50%	600 32%	5 28%	367 20%	0 0%	69 4%	4 22%	869 47%	0 0%	2 0%
APR-2015	7 50%	628 33%	4 29%	373 20%	2 14%	67 4%	1 7%	862 45%	0 0%	2 0%
MAY-2015	11 65%	665 34%	4 24%	382 20%	1 6%	70 4%	2 12%	864 44%	0 0%	2 0%
JUN-2015	15 56%	710 35%	8 30%	396 20%	0 0%	72 4%	4 15%	875 43%	0 0%	1 0%
JUL-2015	11 58%	746 36%	4 21%	404 20%	0 0%	71 3%	4 21%	866 42%	0 0%	1 0%
AUG-2015	11 69%	782 38%	4 25%	413 20%	0 0%	70 3%	1 6%	854 41%	0 0%	1 0%
SEP-2015	17 85%	849 40%	1 5%	412 19%	0 0%	65 3%	2 10%	855 40%	0 0%	1 0%
OCT-2015	14 70%	890 40%	6 30%	435 20%	0 0%	65 3%	0 0%	851 39%	0 0%	1 0%
NOV-2015	15 71%	940 42%	6 29%	439 19%	0 0%	67 3%	0 0%	854 38%	0 0%	1 0%
DEC-2015	11 50%	990 43%	10 45%	446 19%	0 0%	66 3%	1 5%	841 37%	0 0%	1 0%
JAN-2016	6 55%	1022 44%	4 36%	462 20%	0 0%	67 3%	1 9%	822 35%	0 0%	1 0%
FEB-2016	7 64%	1065 45%	4 36%	469 20%	0 0%	61 3%	0 0%	813 34%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2015	2347	34.81	2123	31.49	1137	16.86	179	2.65	74	1.10	882	13.08
FEB-2015	2363	34.79	2110	31.07	1176	17.31	178	2.62	73	1.07	892	13.13
MAR-2015	2398	35.07	2112	30.89	1203	17.60	184	2.69	67	0.98	873	12.77
APR-2015	2391	34.91	2095	30.59	1239	18.09	184	2.69	67	0.98	873	12.75
MAY-2015	2397	34.80	2094	30.40	1277	18.54	179	2.60	68	0.99	873	12.67
JUN-2015	2367	34.29	2078	30.11	1323	19.17	172	2.49	72	1.04	890	12.89
JUL-2015	2372	34.24	2068	29.85	1352	19.52	171	2.47	67	0.97	897	12.95
AUG-2015	2367	34.19	2044	29.52	1382	19.96	168	2.43	70	1.01	893	12.90
SEP-2015	2324	33.56	2032	29.35	1446	20.88	168	2.43	64	0.92	890	12.85
OCT-2015	2327	33.43	2006	28.82	1492	21.44	167	2.40	64	0.92	904	12.99
NOV-2015	2322	33.09	2014	28.70	1543	21.99	160	2.28	67	0.95	911	12.98
DEC-2015	2292	32.76	1984	28.36	1582	22.61	161	2.30	62	0.89	915	13.08
JAN-2016	2292	32.81	1948	27.88	1614	23.10	158	2.26	61	0.87	913	13.07
FEB-2016	2287	32.68	1927	27.54	1668	23.84	153	2.19	59	0.84	904	12.92

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2015	24	2	2	8	3	9	370
FEB-2015	36	3	3	9	3	16	469
MAR-2015	29	2	5	5	8	7	386
APR-2015	28	8	3	4	3	10	335
MAY-2015	33	4	6	9	5	8	290
JUN-2015	36	6	2	8	8	11	370
JUL-2015	25	6	2	2	6	7	380
AUG-2015	19	2	3	4	2	7	400
SEP-2015	32	7	1	5	2	15	505
OCT-2015	25	5	2	3	4	9	430
NOV-2015	29	5	1	5	6	10	400
DEC-2015	22	2	3	4	5	7	370
JAN-2016	18	2	3	0	5	5	400
FEB-2016	18	4	0	6	3	5	331

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2015	10391	2659
FEB-2015	10437	2666
MAR-2015	10476	2675
APR-2015	10496	2687
MAY-2015	10550	2711
JUN-2015	10636	2758
JUL-2015	10705	2806
AUG-2015	10771	2862
SEP-2015	10856	2917
OCT-2015	10908	2957
NOV-2015	10971	2997
DEC-2015	11017	3024
JAN-2016	11051	3052
FEB-2016	11145	3135

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
February 2016

N = 6998

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2016

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2016

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2016

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2016

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2016

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	33	45	22
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	69	90	51	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	323	427	251	
THOMPSON/CARIBOO/ SHUSWAP	0-19	5	5	0
	20-34	21	21	16
	35-49	55	65	45
	50+	91	135	76
Total HSDA:	172	226	137	
Total HA:		597	788	461

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	*
	20-34	50	51	*
	35-49	177	210	*
	50+	360	517	*
Total HA:		597	788	461

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	461	622	362
Female	136	166	99

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	461	53	550	35

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	17	10
	5 years or more	6	5
	<5 years	10	7
	Total HSDA:	33	22
KOOTENAY BOUNDARY	10 years or more	34	23
	5 years or more	20	17
	<5 years	15	11
	Total HSDA:	69	51
OKANAGAN	10 years or more	169	120
	5 years or more	74	58
	<5 years	80	73
	Total HSDA:	323	251
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	88	62
	5 years or more	34	31
	<5 years	50	44
	Total HSDA:	172	137
Total HA:		597	461

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	308	215
	5 years or more	134	111
	<5 years	155	135
Total HA:		597	461

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	35	50	12	23
KOOTENAY BOUNDARY	63	110	28	43
OKANAGAN	195	666	67	241
THOMPSON/CARIBOO/SHUSWAP	125	410	47	109
Total:	418	1236	154	416

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	0
KOOTENAY BOUNDARY	12
OKANAGAN	45
THOMPSON/CARIBOO/SHUSWAP	37
Total:	94

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	5
	20-34	29	30	20
	35-49	114	124	86
	50+	170	231	140
	Total HSDA:		320	392
FRASER NORTH	0-19	18	18	*
	20-34	113	114	*
	35-49	360	410	*
	50+	453	710	*
	Total HSDA:		944	1252
FRASER SOUTH	0-19	10	10	6
	20-34	99	101	73
	35-49	358	408	293
	50+	416	619	348
	Total HSDA:		883	1138
Total HA:		2147	2782	1705

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	35	35	15
	20-34	241	245	186
	35-49	832	942	640
	50+	1039	1560	864
Total HA:		2147	2782	1705

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1626	2137	1323
Female	521	645	382

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1705	50	600	35

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	148	112
	5 years or more	88	69
	<5 years	84	70
	Total HSDA:	320	251
FRASER NORTH	10 years or more	453	330
	5 years or more	239	195
	<5 years	252	209
	Total HSDA:	944	734
FRASER SOUTH	10 years or more	401	313
	5 years or more	243	205
	<5 years	239	202
	Total HSDA:	883	720
Total HA:		2147	1705

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1002	755
	5 years or more	570	469
	<5 years	575	481
Total HA:		2147	1705

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	126	402	43	82
FRASER NORTH	228	1396	63	267
FRASER SOUTH	201	1172	45	333
Total:	555	2970	151	682

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	184
FRASER NORTH	614
FRASER SOUTH	498
Total:	1296

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	19
	35-49	*	*	66
	50+	*	*	171
	Total HSDA:		303	438
RICHMOND	0-19	5	5	*
	20-34	24	24	*
	35-49	46	49	*
	50+	75	114	*
	Total HSDA:	150	192	121
VANCOUVER	0-19	56	59	7
	20-34	401	409	317
	35-49	1591	1849	1178
	50+	2407	4007	1909
	Total HSDA:	4455	6324	3411
Total HA:		4908	6954	3788

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	63	66	8
	20-34	445	453	357
	35-49	1722	1997	1282
	50+	2678	4438	2141
Total HA:		4908	6954	3788

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4312	6113	3338
Female	594	839	450

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3788	51	610	35

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	167	136
	5 years or more	51	47
	<5 years	85	73
	Total HSDA:	303	256
RICHMOND	10 years or more	70	52
	5 years or more	37	29
	<5 years	43	40
	Total HSDA:	150	121
VANCOUVER	10 years or more	2256	1625
	5 years or more	1110	869
	<5 years	1089	917
	Never on ART	0	0
	Total HSDA:	4455	3411
Total HA:	4908	3788	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2493	1813
5 years or more	1198	945
<5 years	1217	1030
Never on ART	0	0
Total HA:	4908	3788

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	141	367	54	94
RICHMOND	42	259	14	89
VANCOUVER	532	9803	209	5244
Total:	715	10429	277	5427

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	100

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		270	379
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		108	142
SOUTH VANCOUVER ISLAND	0-19	10	10	*
	20-34	42	44	*
	35-49	214	252	*
	50+	382	597	*
	Total HSDA:		648	903
Total HA:		1026	1424	799

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	14	14	5
	20-34	78	83	58
	35-49	331	386	262
	50+	603	941	474
Total HA:		1026	1424	799

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	824	1148	650
Female	202	276	149

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	799	52	480	35

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	130	99
	5 years or more	68	61
	<5 years	72	59
	Total HSDA:	270	219
NORTH VANCOUVER ISLAND	10 years or more	47	35
	5 years or more	28	23
	<5 years	33	27
	Total HSDA:	108	85
SOUTH VANCOUVER ISLAND	10 years or more	322	225
	5 years or more	167	135
	<5 years	159	135
	Total HSDA:	648	495
Total HA:		1026	799

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	499	359
	5 years or more	263	219
	<5 years	264	221
Total HA:		1026	799

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER ISLAND Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	170	718	83	183
NORTH VANCOUVER ISLAND	117	234	50	69
SOUTH VANCOUVER ISLAND	182	1523	50	517
Total:	469	2475	183	769

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	44
NORTH VANCOUVER ISLAND	32
SOUTH VANCOUVER ISLAND	86
Total:	162

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		40	48
NORTH WEST	0-19	*	*	0
	20-34	*	*	7
	35-49	*	*	19
	50+	*	*	22
	Total HSDA:		65	96
NORTHERN INTERIOR	0-19	5	5	*
	20-34	28	31	*
	35-49	69	86	*
	50+	75	121	*
	Total HSDA:		177	243
Total HA:		282	387	209

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	40	48	*
	35-49	110	141	*
	50+	125	191	*
Total HA:		282	387	209

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	175	244	134
Female	107	143	75

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	209	48	490	35

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	15	7
	5 years or more	15	9
	<5 years	10	9
	Total HSDA:	40	25
NORTH WEST	10 years or more	17	6
	5 years or more	27	23
	<5 years	21	19
	Total HSDA:	65	48
NORTHERN INTERIOR	10 years or more	55	34
	5 years or more	51	43
	<5 years	71	59
	Total HSDA:	177	136
Total HA:		282	209

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	87	47
	5 years or more	93	75
	<5 years	102	87
Total HA:		282	209

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	31	58	8	10
NORTH WEST	62	140	18	24
NORTHERN INTERIOR	98	389	25	181
Total:	191	587	51	215

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	15
NORTHERN INTERIOR	20
Total:	41

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	6	*
	OKANAGAN	*	30	*
	THOMPSON/CARIBOO/SHUSWAP	*	35	*
	Total HA:	46	81	37
FRASER	FRASER EAST	31	39	24
	FRASER NORTH	60	89	45
	FRASER SOUTH	70	96	57
	Total HA:	161	224	126
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	22	42	20
	RICHMOND	7	12	5
	VANCOUVER	504	785	418
	Total HA:	533	839	443
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	50	75	39
	NORTH VANCOUVER ISLAND	13	22	9
	SOUTH VANCOUVER ISLAND	33	70	26
	Total HA:	96	167	74
NORTHERN	NORTH EAST	10	12	7
	NORTH WEST	32	55	28
	NORTHERN INTERIOR	62	94	55
	Total HA:	104	161	90
Total:		940	1472	770

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	592	945	480
Female	348	527	290

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	770	49	470	35

* Patients numbers < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Combination Therapy: using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.





Dolutegravir (DTG): an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

Efavirenz (Sustiva, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

Emtricitabine (FTC): a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

Famciclovir (Famvir): a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (MVC, Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.





Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddI (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).





PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a pill that contains DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

Tenofovir (Viread, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare's trade name for a pill that contains DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare's trade name for a pill that contains ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a pill that contains TENOFOVIR and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

